Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0JKJZB |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-B7H4 antibody |
|||||
| Antigen Name | B7-H4 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
BG-C9074 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants (ECOG ≤1) have advanced solid tumors (measurable per RECIST v1.1), adequate organ function, and archived tumor tissue. Exclusions: prior B7H4-ADC/TOP1i-ADC therapy, active CNS metastases (<2cm/stable ≥4 weeks allowed), concurrent malignancies, ≥Grade 2 pneumonitis, uncontrolled infections, or diabetes. Contraception is required during and post-treatment (7 months for females, 4 months for males).
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06233942 | Clinical Status | PHASE1 | ||
| Clinical Description |
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Phase 1a evaluates safety (AE/SAE incidence), determines MTD/MAD of BG-C9074 (±tislelizumab), and establishes RDFE based on toxicity, PK/PD, and antitumor activity. Phase 1b assesses ORR by RECIST v1.1 and RP2D selection, with both phases spanning ~3 years of follow-up.
|
||||
| Other Endpoint |
Secondary endpoints include ORR, DOR, DCR, CBR (confirmed CR/PR/SD ≥24 weeks), and PFS per RECIST v1.1. PK parameters (Cmax, Cmin, Tmax, t½, AUC, CL/F, Vz/F, accumulation) and immunogenicity (ADA) are analyzed over ~3 years, with intensive sampling in the first 4 months.
|
||||
References